Korea finished drug market growth driven by generics

Jul 10, 2018

FDF launches at CPhI Korea as country set to become regional hub The Korean pharma market is experiencing significant growth in finished drug products, according to CPhI Korea. Over the last 12 months, market conditions have spurred a strong expansion in exports of finished formulations, driven primarily by an expanding domestic generics market. South Korea’s domestic companies are transitioning quickly to an export-oriented stance. According to the Korean Pharmaceutical Traders Association (KPTA), the export of domestic finished products is growing with a total volume of $2.6 billion in 2017. Domestic APIs are also seeing steady growth with a total volume ...

Read More

Symcel appoints two new board members to bolster R&D business growth and expansion into the clinical diagnostics market

Jul 3, 2018

Symcel – the company behind the revolutionary cell-based assay tool for real-time cell metabolism measurements, the calScreener™ – has announced the appointment of two new highly experienced board members; Erik Walldén and Stefan Löfås. Both will play a key role in bolstering the full execution of the company’s corporate strategy to grow business in the research market and develop much needed solutions for clinical diagnostics. Erik Walldén, who is internationally recognized for his success in building prosperous life science companies and driving business in the medical technology sector, will play a pivotal role in the implementation of the company’s business, sales ...

Read More

TraceLink Achieves 69% Overall Revenue Growth in Q1 2018, Including 270% Revenue Growth in EMEA

May 16, 2018

TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced financial and company results for the first quarter of 2018.   Financial growth highlights for Q1 2018 include:   A 69 percent year-over-year increase in Q1 revenue, including revenue growth in the following regions: 386 percent revenue growth in APAC; 270 percent revenue growth in EMEA; and, 159 percent revenue growth in India. A 43 percent year-over-year increase in all bookings for Q1, including a 177 percent increase in EMEA bookings for the ...

Read More

CPhI Global Pharma Index: India’s reputation improving and ranks third most competitive nation

Nov 10, 2017

CPhI & P-MEC India – organised by UBM – is set to welcome more than 50,000 attendees as the CPhI Global Pharma Index shows the country’s efforts to improve its reputation are paying dividends. India emerged successful in a number of key areas and was ranked by international pharma companies as the third most competitive nation globally.   The inaugural CPhI Global Pharma Index – a reputation audit – draws on the insights of 500 international pharmaceutical companies from over 40 countries to rank the major pharma economies out of ten across a spread of criteria.   These findings are announced as the ...

Read More